These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36228881)

  • 1. Physicochemical surrogates for in vitro toxicity assessment of liposomal amphotericin B.
    Marx R; Lee J; Svirkin Y; Yoon S; Landrau N; Abul Kaisar M; Qin B; Park JH; Alam K; Kozak D; Wang Y; Xu X; Zheng J; Rivnay B
    Int J Pharm; 2022 Nov; 628():122273. PubMed ID: 36228881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphotericin B release rate is the link between drug status in the liposomal bilayer and toxicity.
    Svirkin Y; Lee J; Marx R; Yoon S; Landrau N; Kaisar MA; Qin B; Park JH; Alam K; Kozak D; Wang Y; Xu X; Zheng J; Rivnay B
    Asian J Pharm Sci; 2022 Jul; 17(4):544-556. PubMed ID: 36105314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Critical process parameters in manufacturing of liposomal formulations of amphotericin B.
    Rivnay B; Wakim J; Avery K; Petrochenko P; Myung JH; Kozak D; Yoon S; Landrau N; Nivorozhkin A
    Int J Pharm; 2019 Jun; 565():447-457. PubMed ID: 31071418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long chain fatty acid conjugation remarkably decreases the aggregation induced toxicity of Amphotericin B.
    Thanki K; Prajapati R; Sangamwar AT; Jain S
    Int J Pharm; 2018 Jun; 544(1):1-13. PubMed ID: 29635057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical method development and comparability study for AmBisome® and generic Amphotericin B liposomal products.
    Liu Y; Mei Z; Mei L; Tang J; Yuan W; Srinivasan S; Ackermann R; Schwendeman AS
    Eur J Pharm Biopharm; 2020 Dec; 157():241-249. PubMed ID: 32980448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amphotericin B Loaded Nanostructured Lipid Carriers for Parenteral Delivery: Characterization, Antifungal and In vitro Toxicity Assessment.
    Nimtrakul P; Tiyaboonchai W; Lamlertthon S
    Curr Drug Deliv; 2019; 16(7):645-653. PubMed ID: 31362675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cell impedance-based real-time in vitro assay to assess the toxicity of amphotericin B formulations.
    Menotti J; Alanio A; Sturny-Leclère A; Vitry S; Sauvage F; Barratt G; Bretagne S
    Toxicol Appl Pharmacol; 2017 Nov; 334():18-23. PubMed ID: 28865757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of liposomal amphotericin B formulation.
    Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
    J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the freeze-drying process on the physicochemical and biological properties of pre-heated amphotericin B micellar systems.
    Siqueira SD; Silva-Filho MA; Silva CA; Araújo IB; Silva AE; Fernandes-Pedrosa MF; Oliveira AG; Egito ES
    AAPS PharmSciTech; 2014 Jun; 15(3):612-9. PubMed ID: 24510525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
    Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
    Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of serum albumin on the aggregation state and toxicity of amphotericin B.
    Aramwit P; Yu BG; Lavasanifar A; Samuel J; Kwon GS
    J Pharm Sci; 2000 Dec; 89(12):1589-93. PubMed ID: 11042607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amphotericin B liposomal formulation: applicable preparation methods, challenges, and tips.
    Seify R; Zahednezhad F; Zakeri-Milani P; Valizadeh H
    Drug Dev Ind Pharm; 2023 Dec; 49(5):367-376. PubMed ID: 37249553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects.
    Charvalos E; Tzatzarakis MN; Van Bambeke F; Tulkens PM; Tsatsakis AM; Tzanakakis GN; Mingeot-Leclercq MP
    J Antimicrob Chemother; 2006 Feb; 57(2):236-44. PubMed ID: 16361329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-Assembled Teicoplanin Micelles as Amphotericin B Nanocarrier.
    Leonhard V; Comini LR; Alasino RV; Cometto MJ; Bierbrauer KL; Beltramo DM
    J Pharm Sci; 2023 Apr; 112(4):1081-1088. PubMed ID: 36528112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.
    Mohamed HA; Radwan RR; Raafat AI; Ali AE
    Drug Deliv Transl Res; 2018 Feb; 8(1):191-203. PubMed ID: 29280061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphotericin B formulations and drug targeting.
    Torrado JJ; Espada R; Ballesteros MP; Torrado-Santiago S
    J Pharm Sci; 2008 Jul; 97(7):2405-25. PubMed ID: 17893903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced antifungal effects of amphotericin B-TPGS-b-(PCL-ran-PGA) nanoparticles in vitro and in vivo.
    Tang X; Zhu H; Sun L; Hou W; Cai S; Zhang R; Liu F
    Int J Nanomedicine; 2014; 9():5403-13. PubMed ID: 25473279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation.
    Gangadhar KN; Adhikari K; Srichana T
    Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection.
    Kaur K; Kumar P; Kush P
    Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a flow-through USP 4 apparatus drug release assay for the evaluation of amphotericin B liposome.
    Tang J; Srinivasan S; Yuan W; Ming R; Liu Y; Dai Z; Noble CO; Hayes ME; Zheng N; Jiang W; Szoka FC; Schwendeman A
    Eur J Pharm Biopharm; 2019 Jan; 134():107-116. PubMed ID: 30481559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.